G6pdN126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker‐Induced Pulmonary Vascular Disease

G6pdN126D Variant Increases the Risk of Developing VEGFR (Vascular Endothelial Growth Factor Receptor) Blocker‐Induced Pulmonary Vascular Disease

Background G6PD (glucose‐6‐phosphate‐dehydrogenase) is a key enzyme in the glycolytic pathway and has been implicated in the pathogenesis of cancer and pulmonary hypertension‐associated vascular remodeling. Here, we investigated the role of an X‐linked G6pd mutation (N126D polymorphism), which is kn...

Full description

Bibliographic Details
Main Authors: Christina Signoretti, Shun Matsumura, Samuel Fatehi, Melinee D'Silva, Rajamma Mathew, Francesca Cendali, Angelo D'Alessandro, S. M. Shafiqul Alam, Victor Garcia, Joseph M. Miano, Sachin A. Gupte
Format: Article
Language:English
Published: Wiley 2024-10-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
metabolic reprogramming
NOS3
PAI‐1
pulmonary hypertension
Serpine1
thrombosis
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.123.035174

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.123.035174

Similar Items